Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• metabolic syndrome (according to National Cholesterol Education Program (NCEP) Adenosine triphosphate (ATP) Ill criteria)

• LDL-Cholesterol > 130mg/dl

• HDL-Cholesterol < 40mg/dl in males and <50mg/dl in females

• Triglycerides < 400 mg/dl

Exclusion Criteria:

• With a concomitant coronary disease

• Currently under statin therapy or previously treated with statins within the last 6 months